Favipiravir (T-705) protects against Nipah virus infection in the hamster model /631/326/22/1295 /631/326/596/1296 /13/106 /14/35 /38/77 /82/51 /96/63 article

Brian E. Dawes, Birte Kalveram, Tetsuro Ikegami, Terry Juelich, Jennifer K. Smith, Lihong Zhang, Arnold Park, Benhur Lee, Takashi Komeno, Yousuke Furuta, Alexander Freiberg

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Nipah and Hendra viruses are recently emerged bat-borne paramyxoviruses (genus Henipavirus) causing severe encephalitis and respiratory disease in humans with fatality rates ranging from 40-75%. Despite the severe pathogenicity of these viruses and their pandemic potential, no therapeutics or vaccines are currently approved for use in humans. Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe. Favipiravir has demonstrated efficacy against a broad spectrum of RNA viruses, including members of the Paramyxoviridae, Filoviridae, Arenaviridae families, and the Bunyavirales order. We now demonstrate that favipiravir has potent antiviral activity against henipaviruses. In vitro, favipiravir inhibited Nipah and Hendra virus replication and transcription at micromolar concentrations. In the Syrian hamster model, either twice daily oral or once daily subcutaneous administration of favipiravir for 14 days fully protected animals challenged with a lethal dose of Nipah virus. This first successful treatment of henipavirus infection in vivo with a small molecule drug suggests that favipiravir should be further evaluated as an antiviral treatment option for henipavirus infections.

Original languageEnglish (US)
Article number7604
JournalScientific Reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Nipah Virus
Virus Diseases
Cricetinae
Henipavirus Infections
Henipavirus
Hendra Virus
Antiviral Agents
Filoviridae
Arenaviridae
Paramyxoviridae
Phase III Clinical Trials
RNA Viruses
Mesocricetus
Pandemics
Encephalitis
Virus Replication
Human Influenza
Virulence
favipiravir
Japan

ASJC Scopus subject areas

  • General

Cite this

Favipiravir (T-705) protects against Nipah virus infection in the hamster model /631/326/22/1295 /631/326/596/1296 /13/106 /14/35 /38/77 /82/51 /96/63 article. / Dawes, Brian E.; Kalveram, Birte; Ikegami, Tetsuro; Juelich, Terry; Smith, Jennifer K.; Zhang, Lihong; Park, Arnold; Lee, Benhur; Komeno, Takashi; Furuta, Yousuke; Freiberg, Alexander.

In: Scientific Reports, Vol. 8, No. 1, 7604, 01.12.2018.

Research output: Contribution to journalArticle

Dawes, Brian E. ; Kalveram, Birte ; Ikegami, Tetsuro ; Juelich, Terry ; Smith, Jennifer K. ; Zhang, Lihong ; Park, Arnold ; Lee, Benhur ; Komeno, Takashi ; Furuta, Yousuke ; Freiberg, Alexander. / Favipiravir (T-705) protects against Nipah virus infection in the hamster model /631/326/22/1295 /631/326/596/1296 /13/106 /14/35 /38/77 /82/51 /96/63 article. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{b59e91edf0cc4d3ea208342477700e5f,
title = "Favipiravir (T-705) protects against Nipah virus infection in the hamster model /631/326/22/1295 /631/326/596/1296 /13/106 /14/35 /38/77 /82/51 /96/63 article",
abstract = "Nipah and Hendra viruses are recently emerged bat-borne paramyxoviruses (genus Henipavirus) causing severe encephalitis and respiratory disease in humans with fatality rates ranging from 40-75{\%}. Despite the severe pathogenicity of these viruses and their pandemic potential, no therapeutics or vaccines are currently approved for use in humans. Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe. Favipiravir has demonstrated efficacy against a broad spectrum of RNA viruses, including members of the Paramyxoviridae, Filoviridae, Arenaviridae families, and the Bunyavirales order. We now demonstrate that favipiravir has potent antiviral activity against henipaviruses. In vitro, favipiravir inhibited Nipah and Hendra virus replication and transcription at micromolar concentrations. In the Syrian hamster model, either twice daily oral or once daily subcutaneous administration of favipiravir for 14 days fully protected animals challenged with a lethal dose of Nipah virus. This first successful treatment of henipavirus infection in vivo with a small molecule drug suggests that favipiravir should be further evaluated as an antiviral treatment option for henipavirus infections.",
author = "Dawes, {Brian E.} and Birte Kalveram and Tetsuro Ikegami and Terry Juelich and Smith, {Jennifer K.} and Lihong Zhang and Arnold Park and Benhur Lee and Takashi Komeno and Yousuke Furuta and Alexander Freiberg",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-25780-3",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Favipiravir (T-705) protects against Nipah virus infection in the hamster model /631/326/22/1295 /631/326/596/1296 /13/106 /14/35 /38/77 /82/51 /96/63 article

AU - Dawes, Brian E.

AU - Kalveram, Birte

AU - Ikegami, Tetsuro

AU - Juelich, Terry

AU - Smith, Jennifer K.

AU - Zhang, Lihong

AU - Park, Arnold

AU - Lee, Benhur

AU - Komeno, Takashi

AU - Furuta, Yousuke

AU - Freiberg, Alexander

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Nipah and Hendra viruses are recently emerged bat-borne paramyxoviruses (genus Henipavirus) causing severe encephalitis and respiratory disease in humans with fatality rates ranging from 40-75%. Despite the severe pathogenicity of these viruses and their pandemic potential, no therapeutics or vaccines are currently approved for use in humans. Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe. Favipiravir has demonstrated efficacy against a broad spectrum of RNA viruses, including members of the Paramyxoviridae, Filoviridae, Arenaviridae families, and the Bunyavirales order. We now demonstrate that favipiravir has potent antiviral activity against henipaviruses. In vitro, favipiravir inhibited Nipah and Hendra virus replication and transcription at micromolar concentrations. In the Syrian hamster model, either twice daily oral or once daily subcutaneous administration of favipiravir for 14 days fully protected animals challenged with a lethal dose of Nipah virus. This first successful treatment of henipavirus infection in vivo with a small molecule drug suggests that favipiravir should be further evaluated as an antiviral treatment option for henipavirus infections.

AB - Nipah and Hendra viruses are recently emerged bat-borne paramyxoviruses (genus Henipavirus) causing severe encephalitis and respiratory disease in humans with fatality rates ranging from 40-75%. Despite the severe pathogenicity of these viruses and their pandemic potential, no therapeutics or vaccines are currently approved for use in humans. Favipiravir (T-705) is a purine analogue antiviral approved for use in Japan against emerging influenza strains; and several phase 2 and 3 clinical trials are ongoing in the United States and Europe. Favipiravir has demonstrated efficacy against a broad spectrum of RNA viruses, including members of the Paramyxoviridae, Filoviridae, Arenaviridae families, and the Bunyavirales order. We now demonstrate that favipiravir has potent antiviral activity against henipaviruses. In vitro, favipiravir inhibited Nipah and Hendra virus replication and transcription at micromolar concentrations. In the Syrian hamster model, either twice daily oral or once daily subcutaneous administration of favipiravir for 14 days fully protected animals challenged with a lethal dose of Nipah virus. This first successful treatment of henipavirus infection in vivo with a small molecule drug suggests that favipiravir should be further evaluated as an antiviral treatment option for henipavirus infections.

UR - http://www.scopus.com/inward/record.url?scp=85047085438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047085438&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-25780-3

DO - 10.1038/s41598-018-25780-3

M3 - Article

AN - SCOPUS:85047085438

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 7604

ER -